Member Profile

Meridigen Biotech Co., Ltd. (Meridigen) is dedicated to developing mesenchymal stem cell-based technologies from manufacturing, testing, and storage, to drug discovery and product development. To ensure the quality of umbilical cord mesenchymal stem cell (UC-MSC) therapeutics, we have been diligently working on the optimization of UC-MSC manufacturing and quality management, from raw materials all the way to final products, every stage of production is strictly in compliance with the Guidance for cellular therapeutics from Taiwan FDA and administrations of other countries such as USFDA and CFDA, as well as the Pharmaceutical Inspection Co-operation Scheme Good Manufacturing Practice, PIC/S GMP. Moreover, the US and Taiwan FDA’s acceptance of our IND for UMC119-01 proves that our UC-MSC Chemistry, Manufacturing and Controls (CMC) and quality conform with current National and International Standards. In addition, Meridigen has established an appropriate IP management system that serves as a niche of our stem cells-based drugs. So far we have had 7 patents and 22 pending patents. Meridigen was founded in Taiwan, yet with an aim at the global market opportunity. Led by Chairman John Hsuan and President Yogi Hsuan, we have expanded its business of stem cell research. To facilitate the development of stem cell therapeutics, Meridigen is collaborated with cross-straits industry and academia and anticipates to lunch stem cell products for the greater wellbeing of mankind.